跳至主要内容
临床试验/CTRI/2024/06/069541
CTRI/2024/06/069541尚未招募2 期

Effect of Metformin therapy on progression of Autosomal Dominant Polycystic Kidney Disease: an open label 2: 1 randomized controlled trial - NI

IPGMER and SSKM hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Patients with ADPKD defined as per case definition between 18-65 years
  • 2. eGFR > 45 ml/min/1.73 m2 as per CKD EPI 2021 equation.
  • 3. Typical or Class 1 ADPKD on MRI.

排除标准

  • 1. Patients with Diabetes mellitus.
  • 2. Patients with liver disease (elevation of liver enzymes >2 times the baseline).
  • 3. Females who were pregnant or breast feeding or unwilling to use contraception.
  • 4. Congestive heart failure,
  • 5. Unable to undergo MR imaging.
  • 6. Subjects those were taking medications that interact with metformin like digoxin,
  • quinidine, cimetidine.
  • 7. Known hypersensitivity to metformin and its derivatives.
  • 8. Psychiatric disorders and any condition that might prevent full comprehension of the
  • purposes and risks of the study.
  • 9. HIV, HBV, HCV infection.
  • 10. Urinary tract obstruction.
  • 11. Atypical Type 2 ADPKD on MRI

研究者

发起方
IPGMER and SSKM hospital

相似试验